Dr. Reddy’s Introduces Novel Acid-Blocker Tegoprazan (PCAB®) in India to Combat Widespread Acid Peptic Diseases

Dr. Reddy’s Laboratories Ltd. has announced a significant advancement in the treatment of acid-related gastrointestinal diseases in India with the launch of the novel molecule Tegoprazan under the brand name PCAB® (50 mg). This new-generation potassium-competitive acid blocker is poised to offer a much-needed solution for millions suffering from conditions such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD), and Gastric Ulcer.

Addressing a Critical Need in India

Acid Peptic Diseases (APD) are a prevalent health concern in India, affecting approximately 38% of the population. This high incidence underscores the urgent need for more effective and fast-acting treatment options. Tegoprazan is designed to address this gap by inducing a rapid onset of action and maintaining prolonged gastric pH control, potentially leading to significant clinical benefits for patients.

Clinical Efficacy and Global Presence

The efficacy of Tegoprazan has been validated through a multinational clinical trial conducted by Dr. Reddy’s across India, South Africa, and Russia. A remarkable 99% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8, demonstrating its potent therapeutic capabilities.

Tegoprazan has already garnered international recognition, having been approved in 21 countries, including South Korea and China. It is currently undergoing registration in several other countries and has successfully completed its Phase-III trial in the United States, indicating its global potential and robust clinical profile.

Strategic Partnership for Enhanced Patient Care

The launch of PCAB® in India is a result of a strategic partnership between Dr. Reddy’s and HK inno.N Corporation. M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, highlighted the company’s commitment to innovation in gastrointestinal diseases, a key focus area. “Our partnership with HK inno.N Corporation for Tegoprazan brings together complementary strengths to enhance patient access to an innovative molecule that addresses critical gaps in acid peptic disease management and improves outcomes,” Ramana stated.

Echoing this sentiment, Dal-Won Kwak, Chief Executive Officer, HK inno.N Corporation, expressed his honor in introducing Tegoprazan to the Indian market, recognizing it as one of the world’s most significant pharmaceutical markets. Kwak is confident that PCAB® will establish itself as a leading innovative therapy within the potassium-competitive acid blockers class in India, offering a valuable new treatment option and contributing significantly to the improvement of gastrointestinal care.

This launch reinforces Dr. Reddy’s strong and trusted presence in the gastrointestinal segment, complementing its existing portfolio of well-established brands like Omez®, Razo®, and Vono™. Tegoprazan is expected to be a game-changer for patients suffering from acid-related gastrointestinal disorders in India.